Use of plasma levels for antiepileptic drug monitoring in clinical practice

E. Beghi, D. Trevisan, G. Tognoni, S. Arrigoni, G. Bogliun, L. G. Bongiovanni, S. Borgheresi, M. Benedetti, G. Beretta, A. Bianchi, U. Bocci, D. Buti, M. Buttiglione, G. Cagnin, C. Cardinali, G. Chiodelli, C. Ciampi, U. Colangelo, V. Crespi, C. A. De Fanti & 22 others P. Ferri, D. Galeone, G. Giuliani, A. La Neve, C. Lenti, V. Lepore, M. Lini, A. Ortenzi, T. Perniola, L. Piattella, D. Porazzi, A. Quattrini, M. R. Rottoli, R. Silvestri, L. M. Specchio, F. Spinogatti, V. Toso, M. Trizio, G. Zaccara, P. Zagnoni, N. Zamponi, P. Zolo

Research output: Contribution to journalArticle

Abstract

A multi-center survey of antepileptic treatment was conducted in Italy on 245 previously untreated ("new") patients with epilepsy and 355 patients treated for more than three months ("old" patients). Therapeutic drug monitoring (TDM) of antiepileptic drugs was evaluated in the context of routine clinical conditions, in relation to individual therapeutic problems and mode of treatment. Plasma levels (PL) were determined in 75% of "new" patients and 78% of "old" patients, with wide intercenter variability. TDM was done at 69% of the follow-up attendences for "new" patients and at 34% for "old" patients, but was apparently unrelated to specific therapeutic problems, such as poor disease control or adverse drug reactions. Plasma drug concentration measurements were made more often among patients on polytherapy. The age of the patient and the time elapsing since diagnosis did not seem to affect request patterns significantly. From these findings it appears that TDM is largerly influenced by factors unrelated to the common recommendations in the literature. In addition, the use of TDM in clinical practice reflects the limitations of the available techniques.

Original languageEnglish
Pages (from-to)59-65
Number of pages7
JournalItalian Journal of Neurological Sciences
Volume13
Issue number1
DOIs
Publication statusPublished - Feb 1992

Fingerprint

Drug Monitoring
Anticonvulsants
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Italy
Epilepsy

Keywords

  • Anticonvulsants-blood
  • drug monitoring
  • epilepsy-occurrence

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Beghi, E., Trevisan, D., Tognoni, G., Arrigoni, S., Bogliun, G., Bongiovanni, L. G., ... Zolo, P. (1992). Use of plasma levels for antiepileptic drug monitoring in clinical practice. Italian Journal of Neurological Sciences, 13(1), 59-65. https://doi.org/10.1007/BF02222890

Use of plasma levels for antiepileptic drug monitoring in clinical practice. / Beghi, E.; Trevisan, D.; Tognoni, G.; Arrigoni, S.; Bogliun, G.; Bongiovanni, L. G.; Borgheresi, S.; Benedetti, M.; Beretta, G.; Bianchi, A.; Bocci, U.; Buti, D.; Buttiglione, M.; Cagnin, G.; Cardinali, C.; Chiodelli, G.; Ciampi, C.; Colangelo, U.; Crespi, V.; De Fanti, C. A.; Ferri, P.; Galeone, D.; Giuliani, G.; La Neve, A.; Lenti, C.; Lepore, V.; Lini, M.; Ortenzi, A.; Perniola, T.; Piattella, L.; Porazzi, D.; Quattrini, A.; Rottoli, M. R.; Silvestri, R.; Specchio, L. M.; Spinogatti, F.; Toso, V.; Trizio, M.; Zaccara, G.; Zagnoni, P.; Zamponi, N.; Zolo, P.

In: Italian Journal of Neurological Sciences, Vol. 13, No. 1, 02.1992, p. 59-65.

Research output: Contribution to journalArticle

Beghi, E, Trevisan, D, Tognoni, G, Arrigoni, S, Bogliun, G, Bongiovanni, LG, Borgheresi, S, Benedetti, M, Beretta, G, Bianchi, A, Bocci, U, Buti, D, Buttiglione, M, Cagnin, G, Cardinali, C, Chiodelli, G, Ciampi, C, Colangelo, U, Crespi, V, De Fanti, CA, Ferri, P, Galeone, D, Giuliani, G, La Neve, A, Lenti, C, Lepore, V, Lini, M, Ortenzi, A, Perniola, T, Piattella, L, Porazzi, D, Quattrini, A, Rottoli, MR, Silvestri, R, Specchio, LM, Spinogatti, F, Toso, V, Trizio, M, Zaccara, G, Zagnoni, P, Zamponi, N & Zolo, P 1992, 'Use of plasma levels for antiepileptic drug monitoring in clinical practice', Italian Journal of Neurological Sciences, vol. 13, no. 1, pp. 59-65. https://doi.org/10.1007/BF02222890
Beghi, E. ; Trevisan, D. ; Tognoni, G. ; Arrigoni, S. ; Bogliun, G. ; Bongiovanni, L. G. ; Borgheresi, S. ; Benedetti, M. ; Beretta, G. ; Bianchi, A. ; Bocci, U. ; Buti, D. ; Buttiglione, M. ; Cagnin, G. ; Cardinali, C. ; Chiodelli, G. ; Ciampi, C. ; Colangelo, U. ; Crespi, V. ; De Fanti, C. A. ; Ferri, P. ; Galeone, D. ; Giuliani, G. ; La Neve, A. ; Lenti, C. ; Lepore, V. ; Lini, M. ; Ortenzi, A. ; Perniola, T. ; Piattella, L. ; Porazzi, D. ; Quattrini, A. ; Rottoli, M. R. ; Silvestri, R. ; Specchio, L. M. ; Spinogatti, F. ; Toso, V. ; Trizio, M. ; Zaccara, G. ; Zagnoni, P. ; Zamponi, N. ; Zolo, P. / Use of plasma levels for antiepileptic drug monitoring in clinical practice. In: Italian Journal of Neurological Sciences. 1992 ; Vol. 13, No. 1. pp. 59-65.
@article{3cb2e6c1425b43d4a21d7f25566e2447,
title = "Use of plasma levels for antiepileptic drug monitoring in clinical practice",
abstract = "A multi-center survey of antepileptic treatment was conducted in Italy on 245 previously untreated ({"}new{"}) patients with epilepsy and 355 patients treated for more than three months ({"}old{"} patients). Therapeutic drug monitoring (TDM) of antiepileptic drugs was evaluated in the context of routine clinical conditions, in relation to individual therapeutic problems and mode of treatment. Plasma levels (PL) were determined in 75{\%} of {"}new{"} patients and 78{\%} of {"}old{"} patients, with wide intercenter variability. TDM was done at 69{\%} of the follow-up attendences for {"}new{"} patients and at 34{\%} for {"}old{"} patients, but was apparently unrelated to specific therapeutic problems, such as poor disease control or adverse drug reactions. Plasma drug concentration measurements were made more often among patients on polytherapy. The age of the patient and the time elapsing since diagnosis did not seem to affect request patterns significantly. From these findings it appears that TDM is largerly influenced by factors unrelated to the common recommendations in the literature. In addition, the use of TDM in clinical practice reflects the limitations of the available techniques.",
keywords = "Anticonvulsants-blood, drug monitoring, epilepsy-occurrence",
author = "E. Beghi and D. Trevisan and G. Tognoni and S. Arrigoni and G. Bogliun and Bongiovanni, {L. G.} and S. Borgheresi and M. Benedetti and G. Beretta and A. Bianchi and U. Bocci and D. Buti and M. Buttiglione and G. Cagnin and C. Cardinali and G. Chiodelli and C. Ciampi and U. Colangelo and V. Crespi and {De Fanti}, {C. A.} and P. Ferri and D. Galeone and G. Giuliani and {La Neve}, A. and C. Lenti and V. Lepore and M. Lini and A. Ortenzi and T. Perniola and L. Piattella and D. Porazzi and A. Quattrini and Rottoli, {M. R.} and R. Silvestri and Specchio, {L. M.} and F. Spinogatti and V. Toso and M. Trizio and G. Zaccara and P. Zagnoni and N. Zamponi and P. Zolo",
year = "1992",
month = "2",
doi = "10.1007/BF02222890",
language = "English",
volume = "13",
pages = "59--65",
journal = "Italian Journal of Neurological Sciences",
issn = "0392-0461",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Use of plasma levels for antiepileptic drug monitoring in clinical practice

AU - Beghi, E.

AU - Trevisan, D.

AU - Tognoni, G.

AU - Arrigoni, S.

AU - Bogliun, G.

AU - Bongiovanni, L. G.

AU - Borgheresi, S.

AU - Benedetti, M.

AU - Beretta, G.

AU - Bianchi, A.

AU - Bocci, U.

AU - Buti, D.

AU - Buttiglione, M.

AU - Cagnin, G.

AU - Cardinali, C.

AU - Chiodelli, G.

AU - Ciampi, C.

AU - Colangelo, U.

AU - Crespi, V.

AU - De Fanti, C. A.

AU - Ferri, P.

AU - Galeone, D.

AU - Giuliani, G.

AU - La Neve, A.

AU - Lenti, C.

AU - Lepore, V.

AU - Lini, M.

AU - Ortenzi, A.

AU - Perniola, T.

AU - Piattella, L.

AU - Porazzi, D.

AU - Quattrini, A.

AU - Rottoli, M. R.

AU - Silvestri, R.

AU - Specchio, L. M.

AU - Spinogatti, F.

AU - Toso, V.

AU - Trizio, M.

AU - Zaccara, G.

AU - Zagnoni, P.

AU - Zamponi, N.

AU - Zolo, P.

PY - 1992/2

Y1 - 1992/2

N2 - A multi-center survey of antepileptic treatment was conducted in Italy on 245 previously untreated ("new") patients with epilepsy and 355 patients treated for more than three months ("old" patients). Therapeutic drug monitoring (TDM) of antiepileptic drugs was evaluated in the context of routine clinical conditions, in relation to individual therapeutic problems and mode of treatment. Plasma levels (PL) were determined in 75% of "new" patients and 78% of "old" patients, with wide intercenter variability. TDM was done at 69% of the follow-up attendences for "new" patients and at 34% for "old" patients, but was apparently unrelated to specific therapeutic problems, such as poor disease control or adverse drug reactions. Plasma drug concentration measurements were made more often among patients on polytherapy. The age of the patient and the time elapsing since diagnosis did not seem to affect request patterns significantly. From these findings it appears that TDM is largerly influenced by factors unrelated to the common recommendations in the literature. In addition, the use of TDM in clinical practice reflects the limitations of the available techniques.

AB - A multi-center survey of antepileptic treatment was conducted in Italy on 245 previously untreated ("new") patients with epilepsy and 355 patients treated for more than three months ("old" patients). Therapeutic drug monitoring (TDM) of antiepileptic drugs was evaluated in the context of routine clinical conditions, in relation to individual therapeutic problems and mode of treatment. Plasma levels (PL) were determined in 75% of "new" patients and 78% of "old" patients, with wide intercenter variability. TDM was done at 69% of the follow-up attendences for "new" patients and at 34% for "old" patients, but was apparently unrelated to specific therapeutic problems, such as poor disease control or adverse drug reactions. Plasma drug concentration measurements were made more often among patients on polytherapy. The age of the patient and the time elapsing since diagnosis did not seem to affect request patterns significantly. From these findings it appears that TDM is largerly influenced by factors unrelated to the common recommendations in the literature. In addition, the use of TDM in clinical practice reflects the limitations of the available techniques.

KW - Anticonvulsants-blood

KW - drug monitoring

KW - epilepsy-occurrence

UR - http://www.scopus.com/inward/record.url?scp=0026506008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026506008&partnerID=8YFLogxK

U2 - 10.1007/BF02222890

DO - 10.1007/BF02222890

M3 - Article

VL - 13

SP - 59

EP - 65

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 1

ER -